1. Home
  2. GO vs GERN Comparison

GO vs GERN Comparison

Compare GO & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grocery Outlet Holding Corp.

GO

Grocery Outlet Holding Corp.

HOLD

Current Price

$10.46

Market Cap

732.0M

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.43

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GO
GERN
Founded
1946
1990
Country
United States
United States
Employees
N/A
258
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
732.0M
808.3M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
GO
GERN
Price
$10.46
$1.43
Analyst Decision
Hold
Hold
Analyst Count
10
3
Target Price
$11.30
$2.17
AVG Volume (30 Days)
2.8M
15.3M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,688,759,000.00
N/A
Revenue This Year
$2.48
$26.91
Revenue Next Year
$3.91
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
7.26
N/A
52 Week Low
$5.66
$1.04
52 Week High
$19.41
$2.01

Technical Indicators

Market Signals
Indicator
GO
GERN
Relative Strength Index (RSI) 69.97 64.53
Support Level $10.21 $1.23
Resistance Level $11.56 $1.46
Average True Range (ATR) 0.40 0.08
MACD 0.05 0.02
Stochastic Oscillator 96.60 87.88

Price Performance

Historical Comparison
GO
GERN

About GO Grocery Outlet Holding Corp.

Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: